Pharma Equity Group takes majority stake in Otiom

Pharma Equity Group A/S is acquiring Otiom A/S. The transaction follows the signing of a Letter of Intent in December 2025, under which PEG intends to purchase either the entire share capital or a controlling stake in the Danish MedTech firm. Otiom, which operates a patented IoT localisation platform for dementia care, currently supplies its technology in twenty‑four countries and maintains a network of thirteen EU distributors. The acquisition represents PEG’s first entry into a commercial MedTech business complementary to its pharmaceutical activities. The acquisition aligns with PEG’s strategy to broaden its portfolio with assets that have shorter commercial timelines than traditional drug development. Otiom’s established market presence, validated technology and near break‑even cash‑flow provide an immediate revenue stream and a platform for geographic scaling. PEG’s expertise in capital markets, regulatory navigation and strategic management is intended to accelerate Otiom’s expansion into additional European markets and to deepen its product offering through integration with existing portfolio resources. Post‑closing, Otiom’s management is expected to remain operationally engaged while PEG issues new shares to the sellers, creating a shared ownership structure. The combined entity aims to leverage centralized strategic governance with decentralized execution, targeting increased unit sales, higher subscription uptake and enhanced data analytics capabilities. Anticipated synergies include shared procurement, joint research on sensor technologies and coordinated sales efforts, which are projected to improve cash‑flow generation and strengthen PEG’s position in the Nordic health‑technology landscape.